Home Prescient Therapeutics Limited (ASX: PTX)

Prescient Therapeutics Limited (ASX: PTX)

    Prescient’s September 2019 Quarterly Update Unveils Encouraging Developments

    Prescient Therapeutics Limited (ASX: PTX) is a clinical-stage oncology company focused on developing personalised medicines as potential novel targeted cancer therapies for a range of...

    Prescient’s Leaders Have A Rich History Of Taking Drugs From Bench To Bedside

    Prescient Therapeutics Limited (ASX: PTX) is an Australian clinical stage oncology company that is into the development of personalised medicines for the treatment of...

    Opportunities In Personalised Medicine Industry On Prescient’s Radar

    Clinical stage oncology company, Prescient Therapeutics Limited (ASX: PTX) is engaged in developing personalised medicines to treat a range of challenging cancers. The company...

    Journey of Prescient Therapeutics in 2019

    Prescient Therapeutics Limited (ASX: PTX) is a clinical-stage oncology company that works on mutation causing cancer. The existing product portfolio of the company includes...

    Prescient Therapeutics’ Cancer Trials Backed By A Robust Product Portfolio

    Clinical stage oncology company Prescient Therapeutics Limited (ASX: PTX) is in the process of developing a breakthrough to traditional therapies by its novel drug...

    Prescient Therapeutics starts Phase 1b clinical trial of its unique inhibitor PTX-100

    On 11 July 2019, Prescient Therapeutics Limited (ASX: PTX) announced the commencement of a Phase 1b trial of its second targeted anti-cancer drug PTX-100...

    Prescient Therapeutics’ drug candidates addressing the mutations causing cancer

    Clinical-Stage oncology company, Prescient Therapeutics Limited (ASX: PTX) bases the foundation of its business model on the ground-breaking technology that addresses the mutations causing...

    All that investors need to know about clinical stage oncology company, Prescient Therapeutics

    Prescient Therapeutics Limited (ASX: PTX), based in South Melbourne, Australia, is an oncology company (clinical-stage) that develops novel drugs and targeted therapies to treat...

    Prescient Therapeutics Announces The Receipts of R&D Tax Rebate

    On 15 January 2019, Prescient Therapeutics Limited (ASX: PTX) announced that the company had received Tax Incentive rebate on research and development for the...

    Recent News